Monitoring blood flow alterations in the Tg2576 mouse model of Alzheimer's disease by in vivo magnetic resonance angiography at 17.6T

NeuroImage

Volumn 60, Issue 2, 2012, Pages 958-966

  Kara, F ^a   van Dongen, E S ^a   Schliebs, R ^b   van Buchem, M A ^c   de Groot, H J M ^a   Alia, A ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Magnetic field strength; Magnetic resonance angiography; Transgenic mouse; Vascular alterations

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR COMMUNICATING ARTERY; ARTICLE; BLOOD VESSEL DIAMETER; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; IN VIVO STUDY; MAGNETIC FIELD; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

AGE FACTORS; ALZHEIMER DISEASE; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, TRANSGENIC; REGIONAL BLOOD FLOW;

EID: 84856977681     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.12.055     Document Type: Article

References (58)

1. Anderson C.M., Saloner D., Tsuruda J.S., Shapeero L.G., Lee R.E. Artifacts in maximum-intensity-projection display of MR angiograms. AJR Am. J. Roentgenol. 1990, 154:623-629.
2. Beckmann N. Probing cerebrovascular alterations in Alzheimer's disease using MRI: from transgenic models to patients. Curr. Med. Imaging Rev. 2011, 7:51-61.
3. Beckmann N., Stirnimann R., Bochelen D. High-resolution magnetic resonance angiography of the mouse brain: application to murine focal cerebral ischemia models. J. Magn. Reson. 1999, 140:442-450.
4. Beckmann N., Schuler A., Mueggler T., Meyer E.P., Wiederhold K.H., Staufenbiel M., Krucker T. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J. Neurosci. 2003, 23:8453-8459.
5. Beckmann N., Gerard C., Abramowski D., Cannet C., Staufenbiel M. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy. J. Neurosci. 2011, 31:1023-1031.
6. Bennett S., Grant M.M., Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J. Alzheimers Dis. 2009, 17:245-257.
7. Biffi A., Greenberg S.M. Cerebral amyloid angiopathy: a systematic review. J. Clin. Neurol. 2011, 7:1-9.
8. Braakman N., Matysik J., van Duinen S.G., Verbeek F., Schliebs R., de Groot H.J., Alia A. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 2006, 24:530-536.
9. Bürger S., Noack M., Kirazov L.P., Kirazov E.P., Naydenov C.L., Kouznetsova E., Yafai Y., Schliebs R. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int. J. Dev. Neurosci. 2009, 27:517-523.
10. Bürger S., Yafai Y., Bigl M., Wiedemann P., Schliebs R. Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the β-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice. Int. J. Dev. Neurosci. 2010, 28:597-604.
11. Burgermeister P., Calhoun M.E., Winkler D.T., Jucker M. Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann. N. Y. Acad. Sci. 2000, 903:307-316.
12. Christie R., Yamada M., Moskowitz M., Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 2001, 158:1065-1071.
13. Domnitz S.B., Robbins E.M., Hoang A.W., Garcia-Alloza M., Hyman B.T., Rebeck G.W., Greenberg S.M., Bacskai B.J., Frosch M.P. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2005, 64:588-594.
14. Dorr A., Sled J.G., Kabani N. Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. Neuroimage 2007, 35:1409-1423.
15. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:5-38.
16. Dydak U., Schar M. MR spectroscopy and spectroscopic imaging: comparing 3.0 T versus 1.5 T. Neuroimaging Clin. N. Am. 2006, 16:269-283.
17. El Tannir El Tayara N.T., Delatour B., Volk A., Dhenain M. Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease. MAGMA 2010, 23:53-64.
18. Elesber A.A., Bonetti P.O., Woodrum J.E., Zhu X.Y., Lerman L.O., Younkin S.G., Lerman A. Bosentan preserves endothelial function in mice overexpressing APP. Neurobiol. Aging 2006, 27:446-450.
19. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996, 46:1592-1596.
20. Franceschi M., Alberoni M., Bressi S., Canal N., Comi G., Fazio F., Grassi F., Perani D., Volonte M.A. Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease. Dementia 1995, 6:32-38.
21. Fushimi Y., Miki Y., Kikuta K., Okada T., Kanagaki M., Yamamoto A., Nozaki K., Hashimoto N., Hanakawa T., Fukuyama H., Togashi K. Comparison of 3.0- and 1.5-T three-dimensional time-of-flight MR angiography in moyamoya disease: preliminary experience. Radiology 2006, 239:232-237.
22. Ghiso J., Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. J. Alzheimers Dis. 2001, 3:65-73.
23. Han B.H., Zhou M.L., Abousaleh F., Brendza R.P., Dietrich H.H., Koenigsknecht-Talboo J., Cirrito J.R., Milner E., Holtzman D.M., Zipfel G.J. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J. Neurosci. 2008, 28:13542-13550.
24. Harigaya Y., Tomidokoro Y., Ikeda M., Sasaki A., Kawarabayashi T., Matsubara E., Kanai M., Saido T.C., Younkin S.G., Shoji M. Type-specific evolution of amyloid plaque and angiopathy in APPsw mice. Neurosci. Lett. 2006, 395:37-41.
25. Hawkes C.A., Hartig W., Kacza J., Schliebs R., Weller R.O., Nicoll J.A., Carare R.O. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011, 121:431-443.
26. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med 1986, 3:823-833.
27. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., Danner S., Abramowski D., Sturchler-Pierrat C., Burki K., van Duinen S.G., Maat-Schieman M.L., Staufenbiel M., Mathews P.M., Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004, 7:954-960.
28. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 2000, 47:739-747.
29. Howles G.P., Ghaghada K.B., Qi Y., Mukundan S., Johnson G.A. High-resolution magnetic resonance angiography in the mouse using a nanoparticle blood-pool contrast agent. Magn. Reson. Med. 2009, 62:1447-1456.
30. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
31. Hu X., Norris D.G. Advances in high-field magnetic resonance imaging. Annu. Rev. Biomed. Eng. 2004, 6:157-184.
32. Ishibashi K., Tanaka K., Nakabayashi T., Nakamura M., Uchiyama M., Okawa M. Latent cerebral artery stenoses on magnetic resonance angiography in a patient diagnosed as probable Alzheimer disease. Psychiatry Clin. Neurosci. 1998, 52:93-96.
33. Kantarci K., Jack C.R. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx. 2004, 1(2):196-205.
34. Kumar-Singh S. Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav. 2008, 7:67-82.
35. Kumar-Singh S., Pirici D., McGowan E., Serneels S., Ceuterick C., Hardy J., Duff K., Dickson D., Van Broeckhoven C. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am. J. Pathol. 2005, 167:527-543.
36. Kuo Y.M., Crawford F., Mullan M., Kokjohn T.A., Emmerling M.R., Weller R.O., Roher A.E. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol. Med. 2000, 6:430-439.
37. Kuo Y.M., Beach T.G., Sue L.I., Scott S., Layne K.J., Kokjohn T.A., Kalback W.M., Luehrs D.C., Vishnivetskaya T.A., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Weller R.O., Roher A.E. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol. Med. 2001, 7:609-618.
38. Merlini M., Meyer E.P., Ulmann-Schuler A., Nitsch R.M. Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol. 2011, 10.1007/s00401-011-0834-y.
39. Meyer E.P., Ulmann-Schuler A., Staufenbiel M., Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3587-3592.
40. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
41. Nishitsuji K., Tomiyama T., Ishibashi K., Kametani F., Ozawa K., Okada R., Maat-Schieman M.L., Roos R.A., Iwai K., Mori H. Cerebral vascular accumulation of Dutch-type Abeta42, but not wild-type Abeta42, in hereditary cerebral hemorrhage with amyloidosis, Dutch type. J. Neurosci. Res. 2007, 85:2917-2923.
42. Niwa K., Carlson G.A., Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab. 2000, 20:1659-1668.
43. Okuyama S., Okuyama J., Tamatsu Y., Shimada K., Hoshi H., Iwai J. The arterial circle of Willis of the mouse helps to decipher secrets of cerebral vascular accidents in the human. Med. Hypotheses 2004, 63:997-1009.
44. Park L., Zhou P., Pitstick R., Capone C., Anrather J., Norris E.H., Younkin L., Younkin S., Carlson G., McEwen B.S., Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1347-1352.
45. Pezzini A., Del Zotto E., Volonghi I., Giossi A., Costa P., Padovani A. Cerebral amyloid angiopathy: a common cause of cerebral hemorrhage. Curr. Med. Chem. 2009, 16:2498-2513.
46. Pfeifer L.A., White L.R., Ross G.W., Petrovitch H., Launer L.J. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002, 58:1629-1634.
47. Poduslo J.F., Hultman K.L., Curran G.L., Preboske G.M., Chamberlain R., Marjanska M., Garwood M., Jack C.R., Wengenack T.M. Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. J. Neuropathol. Exp. Neurol. 2011, 70:653-661.
48. Reese T., Bochelen D., Sauter A., Beckmann N., Rudin M. Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed. 1999, 12:189-196.
49. Revesz T., Holton J.L., Lashley T., Plant G., Rostagno A., Ghiso J., Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002, 12:343-357.
50. Schambach S.J., Bag S., Steil V., Isaza C., Schilling L., Groden C., Brockmann M.A. Ultrafast high-resolution in vivo volume-CTA of mice cerebral vessels. Stroke 2009, 40:1444-1450.
51. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
52. Shin H.K., Jones P.B., Garcia-Alloza M., Borrelli L., Greenberg S.M., Bacskai B.J., Frosch M.P., Hyman B.T., Moskowitz M.A., Ayata C. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 2007, 130:2310-2319.
53. Smith E.E., Vijayappa M., Lima F., Delgado P., Wendell L., Rosand J., Greenberg S.M. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology 2008, 71:1424-1430.
54. Thal D.R., Griffin W.S., de Vos R.A., Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008, 115:599-609.
55. Thal D.R., Capetillo-Zarate E., Larionov S., Staufenbiel M., Zurbruegg S., Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging 2009, 30:1936-1948.
56. van de Ven R.C., Hogers B., van den Maagdenberg A.M., de Groot H.J., Ferrari M.D., Frants R.R., Poelmann R.E., van der Weerd L., Kiihne S.R. T(1) relaxation in in vivo mouse brain at ultra-high field. Magn. Reson. Med. 2007, 58:390-395.
57. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000, 20:8-22.
58. Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann. N. Y. Acad. Sci. 2002, 977:37-44.